🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "major milestone" in the effort against increasingly resistant strains of the bacteria, according to scientists.

An International Health Concern

The sexually transmitted infection are on the rise around the world, with estimates suggesting over 82 million new cases annually. Especially elevated rates are observed in the African continent and countries within the WHO's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have hit a all-time high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune development in the reality of rising global incidence, increasing antimicrobial resistance and the highly restricted treatment choices at this time.”

Public health authorities are particularly alarmed about the rise in antibiotic-resistant strains. The global health body has classified it as a "priority pathogen". A tracking program showed that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Therapies Secure Clearance

One new antibiotic, marketed under the name Nuzolvence, was approved by the American regulatory agency in December for combating gonorrhoea. This infection can lead to serious health problems, including infertility. Scientists anticipate that targeted use of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, was also approved in concurrent days. This treatment, which is employed against urinary tract infections, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin stemmed from a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to see it through.

“This authorization represents a huge turning point in the treatment of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Clinical Trial Data and Worldwide Availability

As per results released by a major medical journal, the new drug cured over nine in ten of genital gonorrhoea infections. This puts it on an equal footing with the current standard treatment, which uses two antibiotics. The trial involved nearly 1,000 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, the non-profit has the ability to license and sell the drug in a wide range of low-income and middle-income countries.

Clinicians directly involved have shared positive views. The availability of a one-pill regimen like this is seen as a "critical tool" for gonorrhoea control. This is considered essential to lessen the impact of the infection for patients and to prevent the spread of extremely resistant gonorrhoea around the world.